Research Correlative Studies , MD, PhD CONFIDENTIAL The information in this document is considered privileged and confidential by Inovio Pharmaceuticals and may not be disclosed to others except to the extent neces sary to obtain Institutional Review Board/Ethics committee approval and informed consent, or as required by local regulatory authorities. Persons to whom this information is disclosed must be informed that this information is privileged and confidential and that it should not be further disclosed without the written permission of Inovio Pharmaceuticals. Any supplemental information added to this document is also confidential and proprietary information of Inovio Pharmaceuticals and must be kept in confidence in the same manner as the contents of this document. INO-3112 UPCC # 39313 / HPV -005 Inovio Pharmaceuticals, Inc Clinical Protocol SUMMARY OF CHANGES The following is a list of significant protocol changes from v2 .0 dated June 25, 2015 to v2.1 dated April 8, 2016. All other changes are administrative and do not significantly aff ect the safety of subjects, study scope, or scientific quality of the protocol.